E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Biochemical disturbances (androgens, lipids, bone markers, endocrine) and mood distrubances caused by the use of Oral Contraception (OC). |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the effect of concomitant treatment with dehydroepiandrosterone (50 mg) on mood in women who experience mood disturbances during oral contraception-use. |
|
E.2.2 | Secondary objectives of the trial |
To assess the general effects on well-being; To assess satisfaction and health related quality of life.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Women using oral contraceptives for at least 3 months prior to screening and aged 20-35 years (inclusive) 2. Report of mood disturbances, and attributing this to OC use as evidenced by in depth interview independently performed by two investigators 3. Regular menstrual cycles (24-35 days) prior to last start of OC use 4. Body mass index between (≥) 18 and (≤) 35 kg/m2 5. Good physical and mental health as judged by the Investigator determined by medical and gynaecological history, physical examination, clinical laboratory and vital signs 6. Willing to give informed consent in writing
For the subgroup, inclusion criterion 1 is not applicable and will be adapted to: 1. Women, aged 20-40 years (inclusive), using a non-hormonal contraceptive method for at least 3 months and willing to use an OC for 6 subsequent cycles
|
|
E.4 | Principal exclusion criteria |
1. Androgen therapy during the 6 months prior to screening 2. Use of non-oral hormonal contraception in the 3 months prior to the screening 3. Use of injectable contraceptives (e.g. cyclofem or DMPA) during the 6 months prior to the screening 4. Use within the past 3 months of implanted hormonal contraceptives Mirena® (progestin containing IUD) and Implanon® (subdermal implant delivering etonogestrel) 5. Intention to become pregnant during the study 6. Lactation and/or pregnancy in the previous 6 months prior to screening 7. History of/or current psychiatric disorder which is not related to the use of an OC 8. Treatment for any major psychiatric disorder in the previous 12 months or use of antidepressant medication prior to screening 9. Any clinically significant abnormality following review of medical and gynaecological history, clinical laboratory (haematology, biochemistry and androgen parameters) and physical examination and vital signs 10. Contraindications for contraceptive steroids: - A history of, or existing thromboembolic, cardiovascular or cerebrovascular disorder - A history of, or existing conditions predisposing to, or being prodromi of, a thrombosis - A known defect in the blood coagulation system (e.g. deficiencies in AT-III, protein C, S, APC resistance and Factor V Leiden mutation) - The presence of more than one risk factor for vascular disease (e.g. dyslipoproteinemia; diabetes mellitus; hyperhomocysteinemia; systemic lupus erythematosus; chronic inflammatory bowel disease; antiphospholipid antibodies; smoking; venous thromboembolism in sibling or parent below (<) the age of 50, or arterial disease in sibling or parent below (<) the age of 35; within 2 weeks after full remobilization following surgery) - Hypertension, i.e. systolic blood pressure 140 mmHg and/or diastolic blood pressure 90 mmHg - Disturbance of liver function: cholestatic jaundice, a history of jaundice of pregnancy or jaundice due to previous estrogen use, Rotor syndrome and Dubin-Johnson syndrome - Known or suspected estrogen-dependent tumors or endometrial hyperplasia - Undiagnosed vaginal bleeding - Porphyria - A history during pregnancy or previous estrogen-use of severe pruritus, herpes gestationis or deterioration of otosclerosis 11. Use of one or more of the following medications: - Psychoactive drugs - Antihypertensive drugs - Sex steroids other than the current OC - Use at present or within 30 days before start study medication: hydantoins, barbiturates, primidone, carbamazepine, oxcarbazepine, topiramate, troglitazone, felbamate, rifampicin, rifabutin, griseofulvin, nelfinavir, ritonavir and St. John’s wort (Hypericum perforatum) 12. Administration of any investigational drug within 3 months prior to screening
For the subgroup, exclusion criterion 2 is not applicable and will be adapted to: 2. Use of oral hormonal contraception in the 3 months prior to the screening
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Daily mood rating (1-5) General effect of study medication on subject’s well-being over the past 3 weeks Satisfaction and health related quality of life over de past week of OC intake
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
N=1 study over 6 treatment cycles. |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of trial will be as soon as the last subject has had her final trial visit (visit 9). |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | 0 |